Jeil Pharmaceutical said Wednesday that it has opened a new technology research center in Yongin, Gyeonggi Province, on Monday.
The new research center is part of the company’s plans to strengthen investment in the R&D sector and enhance the development of new drugs and generics
The new center, dedicated to formulation research, has reorganized the existing pharmaceutical and analytical laboratory at Baekam Central Research Laboratory. The company completed the transfer of workforce and equipment last month.
The company expects that the new R&D facility will accelerate the development of new drugs and generic treatments against diabetic, hyperlipidemia, hypertension, benign prostatic hyperplasia and smoking cessation by using advanced technology such as fluidized bed granulator and pellet coating.
“To become a leading global pharmaceutical company, it is essential to develop new drugs through continuous research activities,” Jeil CEO Han Seung-soo said. “Developing competitive products with creative ideas and advanced technologies is the cornerstone for achieving the company’s vision.”
<© Korea Biomedical Review, All rights reserved.>